References

Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress

10.3389/fcvm.2024.1469492 · 2024 · External reference

Cardiovascular implications of MASLD: overview of the evidence

10.1080/00365521.2025.2536585 · 2025 · External reference

Metabolic dysfunction-associated steatotic liver disease and atherosclerosis

10.1007/s11892-024-01542-6 · 2024 · External reference

Metabolic dysfunction-associated steatotic liver disease and the heart

10.1097/hep.0000000000000735 · 2025 · External reference

Prognostic value of coronary artery calcium score for the prediction of atherosclerotic cardiovascular disease in participants with suspected nonalcoholic hepatic steatosis: results from the multi-ethnic study of atherosclerosis

10.1016/j.ahj.2023.07.008 · 2023 · External reference

Coronary and extra-coronary subclinical atherosclerosis to guide lipid-lowering therapy

10.1007/s11883-023-01161-8 · 2023 · External reference

Epicardial adipose tissue: far more than a fat depot

10.3978/j.issn.2223-3652.2014.11.05 · 2014 · External reference

Prognostic value of coronary artery calcium and epicardial adipose tissue assessed by non-contrast cardiac computed tomography

10.1016/j.atherosclerosis.2014.01.038 · 2014 · External reference

Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis

10.1016/j.atherosclerosis.2011.09.041 · 2012 · External reference

Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study

10.1186/s12933-021-01220-x · 2021 · External reference

Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: a cross-sectional, population-based study in middle-aged subjects

10.1371/journal.pone.0202666 · 2018 · External reference

Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes

10.1111/apt.17637 · 2023 · External reference

Inflammatory and metabolic markers mediate the association of hepatic steatosis and fibrosis with 10-year ASCVD risk

10.1080/07853890.2025.2486594 · 2025 · External reference

Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with type 1 diabetes and metabolic dysfunction-associated steatotic liver disease

10.1186/s12933-025-02764-y · 2025 · External reference

Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population

10.1111/jgh.15523 · 2021 · External reference

Impact of nonalcoholic hepatic steatosis on the warranty period of a coronary artery calcium score of 0: results from the multi-ethnic study of atherosclerosis

10.1161/circimaging.123.016465 · 2024 · External reference

A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis

10.1371/journal.pone.0269265 · 2022 · External reference

Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study

10.1210/jc.2016-1525 · 2016 · External reference

Nonalcoholic fatty liver disease is associated with coronary artery calcification

10.1002/hep.25593 · 2012 · External reference

Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease

10.1111/apt.16324 · 2021 · External reference

Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in Eastern China

10.1186/s13098-025-01577-z · 2025 · External reference

Epicardial adipose tissue volume is associated with non-alcoholic fatty liver disease and cardiovascular risk factors in the general population

10.2147/tcrm.s168345 · 2018 · External reference

Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification

10.1038/s41598-024-74287-7 · 2024 · External reference

Visceral obesity and its association with severe coronary artery calcification in patients with metabolic dysfunction-associated steatotic liver disease

10.3390/diagnostics14202305 · 2024 · External reference

From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications

10.3390/biomedicines11030883 · 2023 · External reference

A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement

10.1016/j.jhep.2020.03.039 · 2020 · External reference

MAFLD vs. MASLD: a year in review

10.1080/17446651.2025.2492767 · 2025 · External reference

New nomenclature for nonalcoholic fatty liver disease: understanding metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction- and alcohol-associated liver disease, and their implications in clinical practice

10.1055/s-0044-1785196 · 2024 · External reference

Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis

10.1016/j.dld.2016.09.002 · 2016 · External reference

Association of hepatic steatosis with subclinical atherosclerosis: systematic review and meta-analysis

10.1002/hep4.1199 · 2018 · External reference

Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review

10.1016/j.jhep.2008.06.012 · 2008 · External reference

Fine-needle aspiration of non-Hodgkin’s lymphoma. Southern blot analysis for antigen receptor, bcl-2, and c-myc gene rearrangements

10.1093/ajcp/93.6.754 · 1990 · External reference

The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)

10.1155/2020/3920196 · 2020 · External reference

Epicardial adipose tissue: clinical biomarker of cardio-metabolic risk

10.3390/ijms20235989 · 2019 · External reference

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor

10.5114/ceh.2023.130744 · 2023 · External reference

Utilizing coronary artery calcium to guide statin use

10.1016/j.atherosclerosis.2021.04.011 · 2021 · External reference

Role of coronary artery calcium score in the primary prevention of cardiovascular disease

10.1136/bmj.n776 · 2021 · External reference

Comparison of epicardial adipose tissue radiodensity threshold between contrast and non-contrast enhanced computed tomography scans: a cohort study of derivation and validation

10.1016/j.atherosclerosis.2018.05.013 · 2018 · External reference

Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis

10.1016/s2468-1253(20)30357-5 · 2021 · External reference

Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes

10.1016/j.ultrasmedbio.2010.07.005 · 2010 · External reference

Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease

10.1016/j.cgh.2020.12.016 · 2022 · External reference